Does drug touted by Trump work on COVID-19? After data debacle, we still don’t know By Reuters

© Reuters. FILE PHOTO: The drug hydroxychloroquine, pushed by U.S. President Donald Trump and others in recent months as a possible treatment to people infected with the coronavirus disease (COVID-19), is displayed in Provo

By Kate Kelland and Alistair Smout

LONDON (Reuters) – Scientists are resuming COVID-19 trials of the now world-famous drug hydroxychloroquine, as confusion continues to reign about the anti-malarial hailed by U.S. President Donald Trump as a potential “game-changer” in fighting the pandemic.

The renewed research push follows widespread criticism of the quality of data in a study that on Thursday was retracted. The article, originally published in influential medical journal The Lancet, had found high risks associated with the treatment.

The World Health Organization, which last week paused trials when The Lancet study showed the drug was tied to an increased risk of death in hospitalized patients, said on Wednesday it was ready to resume trials.

Read More

Hedge funds brace for ‘severe rupture’ in markets as valuations diverge from fundamentals

Hedge funds are getting ready for another slump in stock markets after growing uneasy that surging prices do not reflect the economic problems ahead.

Some managers fear that equity investors, used to buying the dips during the decade-long bull market that ended in March’s sharp sell-off, have become too complacent about how quickly economies can recover from the coronavirus crisis and how effective stimulus packages from central banks and governments can be.

The S&P 500 index completed its best 50-day run in history on Wednesday, according to LPL Financial, closing within eight per cent of its record high of mid-February.

“The markets are priced to perfection,” said Danny Yong, founding partner at hedge fund Dymon Asia Capital in Singapore. “The stability in equity markets does not reflect the job losses and the insolvencies ahead of us globally.”

Yong has been buying put options — which protect against market falls by

Read More

The year in leadership: Everything to know about the most recent crop of leaders to score top CEO jobs

In June of 2019, I wrote a story titled “More People Named Jeffrey Got Top CEO Jobs Than Women Last Year.” The piece lamented that of the 23 new leaders that America’s 250 largest companies chose last year, just one––Michelle Gass of Kohl’s––was a woman, so the lone female was outnumbered not just by two gents named Jeffrey but another two named Michael. In 2019, that dismal picture brightened a bit, launching what finally looks like a durable shift to promoting the best talent, regardless of gender. The S&P 250 placed four women in the top job, and while that number may sound low, it’s almost half as many as reached the pinnacle over the previous five years.

That trend is highlighted in The New CEO Report, a yearly study that examines the backgrounds of the leaders who ascended during the prior year to lead S&P 250 companies … Read More